Your Warfarin Dose May Be Wrong. Your Genes Know Why.

VKORC1 encodes vitamin K epoxide reductase, an enzyme that recycles vitamin K in your cells. Vitamin K is essential for making clotting factors. Warfarin works by inhibiting this enzyme, which prevents clotting factor synthesis and thins your blood. This is the mechanism you want. The problem is that some people’s VKORC1 enzyme is inherently more sensitive to warfarin’s inhibition.

The most common variant is -1639G>A in the VKORC1 promoter region. People who carry the A allele, roughly 40% of those of European ancestry, have significantly reduced VKORC1 enzyme activity even before taking warfarin. This means warfarin hits them harder. The A allele is associated with a 50-60% lower warfarin dose requirement compared to people without the variant. Your liver may be processing warfarin normally, but your target tissue is hypersensitive.

In practice, this means you bleed more easily at standard doses. You might notice nosebleeds, bleeding gums, or bruising from minor bumps that shouldn’t cause bleeding. Your INR climbs faster when you take warfarin, and you need a lower maintenance dose. Without knowing you carry this variant, your doctor will keep trying to find a dose that keeps your INR in range, when the real problem is that you need roughly half of what the standard algorithm predicts.

CYP2C9 is one of your liver’s main cytochrome P450 enzymes. It metabolizes roughly 95% of warfarin, converting it into inactive metabolites that your body can excrete. Fast CYP2C9 activity clears warfarin quickly. Slow activity lets warfarin accumulate.

The two most common poor-metabolizer variants are CYP2C9*2 and *3, carried by roughly 5-10% of people of European ancestry. If you have even one *2 or *3 allele, your warfarin metabolism is reduced by 30-50%, depending on which variant and how many copies you carry. Two copies means you’re a poor metabolizer; your liver clears warfarin at a fraction of normal speed. This causes warfarin to accumulate in your bloodstream.

The result is that a standard dose becomes dangerous. Your INR creeps up, sometimes rapidly. You start bleeding. Your doctor thinks you’ve suddenly changed your vitamin K intake or started a new medication, when really your CYP2C9 variants mean you never needed that dose in the first place. People with CYP2C9 poor-metabolizer variants typically need 30-50% lower doses than average.

CYP2C19 metabolizes selective serotonin reuptake inhibitors (SSRIs), proton pump inhibitors (PPIs), and some anticonvulsants. While CYP2C19 doesn’t directly metabolize warfarin, it matters because you might be taking one of these drugs alongside warfarin, and CYP2C19 variants can amplify drug interactions.

Roughly 2-15% of people, depending on ancestry, are poor metabolizers of CYP2C19 (variants *2 or *3). Poor metabolizers accumulate higher levels of SSRIs and PPIs, some of which are known to inhibit warfarin metabolism or increase bleeding risk independently. If you’re taking an SSRI like sertraline for anxiety and you’re a CYP2C19 poor metabolizer, the SSRI reaches higher levels in your blood and increases your bleeding risk on top of warfarin’s own effect.

You might notice that when you started your SSRI, your INR became harder to control even though your warfarin dose stayed the same. Or you started bleeding more easily. Your doctor might blame the interaction without realizing that your specific CYP2C19 variant is making the interaction much worse than it would be in a fast metabolizer.

CYP2D6 is the metabolic workhorse of your liver. It processes roughly 25% of all prescription drugs, including opioids (codeine, tramadol), some antidepressants (venlafaxine, nortriptyline), beta-blockers, and antiarrhythmics. While CYP2D6 doesn’t directly metabolize warfarin, it becomes critical if you need pain control or mood support alongside anticoagulation.

Roughly 7-10% of people of European ancestry are poor metabolizers of CYP2D6 (variants like *4, *5, *10). Poor metabolizers accumulate opioids, antidepressants, and other CYP2D6 substrates, which can increase side effects and, in some cases, trigger serious drug interactions. Some of these drugs can also inhibit warfarin metabolism or increase bleeding risk.

Imagine you’re on warfarin and you develop severe pain or depression after surgery. Your doctor prescribes an opioid or an antidepressant. If you’re a CYP2D6 poor metabolizer, that drug reaches toxic levels. You become sedated, constipated, or bleed more. Your doctor might assume it’s the warfarin’s fault when really it’s a CYP2D6-driven accumulation of the pain or psychiatric medication.

SLCO1B1 encodes a hepatic transporter that pulls statins into your liver cells. Most statins are metabolized in the liver, so getting them into liver cells efficiently is crucial for safety and efficacy. If your SLCO1B1 transporter is slow, statins accumulate in your bloodstream instead of being metabolized.

The most common variant is SLCO1B1*5 (rs4149056 C allele), carried by roughly 15% of people of European ancestry. People with the C allele have reduced statin uptake into the liver, which increases the drug’s exposure throughout your body and elevates the risk of statin myopathy (muscle pain and damage). This risk climbs dramatically with higher-dose simvastatin or pravastatin.

Now add warfarin to the picture. You’re on warfarin for atrial fibrillation, and your cardiologist adds a statin for cholesterol prevention. If you’re an SLCO1B1 poor transporter, the statin accumulates. Your muscles ache, your liver enzyme levels climb, and your doctor considers stopping the statin. Meanwhile, the statin itself can inhibit warfarin metabolism slightly, complicating your anticoagulation further. Knowing your SLCO1B1 status means your cardiologist can choose a statin and dose that works with your genetics.

TPMT metabolizes thiopurine drugs like azathioprine and 6-mercaptopurine, which are immunosuppressants used for autoimmune conditions and some cancers. While you’re less likely to take these alongside warfarin than you are to take SSRIs or statins, they sometimes overlap in patients with autoimmune thrombosis or lupus anticoagulant who need both anticoagulation and immunosuppression.

Roughly 0.3% of people are TPMT poor metabolizers (variants *2, *3A, *3B, *3C). Poor metabolizers accumulate toxic levels of thiopurine metabolites, which can cause severe bone marrow suppression, infections, and death if standard doses are used. This is one of the few pharmacogenomic tests that’s actually life-or-death critical.

If you have autoimmune disease and your doctor prescribes azathioprine to control it while you’re on warfarin, knowing your TPMT status is non-negotiable. A single dose at standard strength can be catastrophic for a poor metabolizer. Genetic testing can identify this before you take even one pill.